Arcutis Biotherapeutics (ARQT) Invested Capital (2020 - 2026)

Arcutis Biotherapeutics' Invested Capital history runs 3 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• In Q1 2026, Invested Capital changed N/A year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $11.0 million (down 89.0% YoY), while the FY2025 annual figure was $1.0 million, changed N/A from the prior year.
• Invested Capital for Q1 2026 stood at $8.0 million, up from $1.0 million in the prior quarter.
• The five-year high for Invested Capital was $99.5 million in Q3 2024, with the low at $1.0 million in Q2 2025.
• The 3-year median for Invested Capital is $1.0 million (2025), against an average of $22.1 million.
• Peak annual rise in Invested Capital reached 99.0% in 2025, while the deepest fall reached 99.0% in 2025.
• Arcutis Biotherapeutics' Invested Capital stood at $99.5 million in 2024, then tumbled by 99.0% to $1.0 million in 2025, then soared by 695.0% to $8.0 million in 2026.
• Business Quant data shows ARQT's Invested Capital at $8.0 million in Q1 2026, $1.0 million in Q4 2025, and $1.0 million in Q3 2025.